All Stories

  1. Persistence and UV inactivation of SARS-CoV-2 in wastewater: Experimental characterization of time, temperature, and aerosolization effects
  2. Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen
  3. Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro
  4. Inhalable spray-dried dry powders combining ivermectin and niclosamide to inhibit SARS-CoV-2 infection in vitro
  5. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections
  6. Neuroproteomic Analysis after SARS-CoV-2 Infection Reveals Overrepresented Neurodegeneration Pathways and Disrupted Metabolic Pathways
  7. Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization
  8. Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection
  9. Health nationalism in Aotearoa New Zealand during COVID-19: problems for global health equity
  10. Alternative options for treatment-experienced people with HIV
  11. Directed Evolution of Seneca Valley Virus in Tumorsphere and Monolayer Cell Cultures of a Small-Cell Lung Cancer Model
  12. Global coordinated surveillance of human pathogens for public health responses to new, emerging, and re-emerging epidemics
  13. Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants
  14. MAIT cells activate dendritic cells to promote TFH cell differentiation and induce humoral immunity
  15. Virology under the Microscope—a Call for Rational Discourse
  16. Virology under the Microscope—a Call for Rational Discourse
  17. Monitoring antiretroviral therapy in low and middle-income countries: current status and future considerations
  18. Influence of management practice on the microbiota of a critically endangered species: a longitudinal study of kākāpō chick faeces and associated nest litter
  19. Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices
  20. Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
  21. Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic
  22. Chikungunya Virus’ High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells
  23. Uncoupling Molecular Testing for SARS-CoV-2 From International Supply Chains
  24. Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda
  25. Ultraviolet-C Irradiation, Heat, and Storage as Potential Methods of Inactivating SARS-CoV-2 and Bacterial Pathogens on Filtering Facepiece Respirators
  26. Incorporation of Sars-Cov-2 Spike Ntd to Rbd-Based Vaccine Improves Immunity and Protection Against Viral Variants
  27. Rapid Response to SARS-CoV-2 in Aotearoa New Zealand: Implementation of a Diagnostic Test and Characterization of the First COVID-19 Cases in the South Island
  28. Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19
  29. High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations
  30. Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection
  31. Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity
  32. In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix
  33. Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria
  34. Nanoscale flow cytometry reveals interpatient variability in HIV protease activity that correlates with viral infectivity and identifies drug-resistant viruses
  35. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda
  36. Tenth Scientific Biennial Meeting of the Australasian Virology Society—AVS10 2019
  37. Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy
  38. Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing
  39. Re-Opening after COVID-19 in New Zealand
  40. In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix
  41. Decreased Enteric Bacterial Composition and Diversity in South American Crohn’s Disease Vary With the Choice of Treatment Strategy and Time Since Diagnosis
  42. Detection of novel HIV-1 drug resistance mutations by support vector analysis of deep sequence data and experimental validation
  43. OC 8450 ABSENCE OF MINORITY HIV-1 DRUG-RESISTANT VARIANTS FOLLOWING MOTHER-TO-CHILD TRANSMISSION DOES NOT PREDICT VIROLOGIC SUCCESS OF FIRST-LINE ANTIRETROVIRAL THERAPY
  44. HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic
  45. First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda
  46. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay
  47. 2267. The Effect of Opportunistic Infection (OI) Prophylaxis on the Gastrointestinal Microbiome (GIM) and Immune Reconstitution (IR) in Veterans With HIV and AIDS
  48. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda
  49. Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Klebsiella pneumoniae Carbapenemase–Producing Klebsiella pneumoniae
  50. Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice
  51. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries
  52. Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease
  53. HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters
  54. Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals
  55. Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa
  56. Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis
  57. Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure
  58. Identifying Variants in GBM: Comparison of ExomeSeq and CCP
  59. BI-29 * VARIANT ANALYSIS OF PRIMARY AND RECURRENT GLIOBLASTOMA USING ION AMPLISEQTM COMPREHENSIVE CANCER PANEL AND WHOLE EXOME SEQUENCING
  60. Deep sequencing: Becoming a critical tool in clinical virology
  61. Role of HIV Minority Variants in Drug Resistance
  62. HIV-1 and GBV-C co-infection in Venezuela
  63. The Role of Viral Genetic Variability in HIV-Associated Neurocognitive Disorder
  64. The Sequencing Continuum for Clinical Research: From Sanger to Next Gen
  65. Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?
  66. Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism
  67. Impact of Resistance Mutations on HIV-1 Replicative Fitness and INSTI Susceptibility
  68. Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism
  69. Comparison of Four NGS Platforms for HIV-1 Coreceptor Tropism Prediction
  70. Editorial: [Hot Topic: Use of Microbicides to Prevent HIV Sexual Transmission (Guest Editor: Miguel E. Quinones-Mateu)]
  71. Mucosal Transmission of Human Immunodeficiency Virus
  72. Virus-inhibitory peptide
  73. Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system
  74. Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides
  75. Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3′Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antire...
  76. Human Immunodeficiency Virus Type 1 Resistance or Cross-Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Currently under Development as Microbicides
  77. Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs
  78. Current tests to evaluate HIV-1 coreceptor tropism
  79. Increased Levels of Human Beta-Defensins mRNA in Sexually HIV-1 Exposed But Uninfected Individuals
  80. Impact on Replicative Fitness of the G48E Substitution in the Protease of HIV-1
  81. Viral Drug Resistance and Fitness
  82. Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations
  83. The impact of viral and host elements on HIV fitness and disease progression
  84. Cystic Fibrosis and Normal Human Airway Epithelial Cell Response to Influenza A Viral Infection.
  85. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness
  86. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors
  87. Role of Human β-defensins in HIV Infection
  88. Virus Fitness: Concept, Quantification, and Application to HIV Population Dynamics
  89. Persistent Replication of Human Immunodeficiency Virus Type 1 despite Treatment of Pulmonary Tuberculosis in Dually Infected Subjects
  90. Is HIV-1 evolving to a less virulent (pathogenic) virus?
  91. The Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 (HIV-1) Group M, HIV-1 Group O, and HIV-2 Isolates
  92. Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection
  93. Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation
  94. HIV-1 mutagenesis during antiretroviral therapy: implications for successful drug treatment
  95. Drug Resistance, Virus Fitness and HIV-1 Mutagenesis
  96. Failure to Detect Human Immunodeficiency Virus Type 1 Superinfection in 28 HIV-Seroconcordant Individuals with High Risk of Reexposure to the Virus
  97. Can HIV-1 superinfection compromise antiretroviral therapy?
  98. Fitness Variations and their Impact on the Evolution of Antiretroviral Drug Resistance
  99. Human epithelial β-defensins 2 and 3 inhibit HIV-1 replication
  100. Role of the Human Immunodeficiency Virus Type 1 Envelope Gene in Viral Fitness
  101. A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy
  102. Role of Baseline pol Genotype in HIV-1 Fitness Evolution
  103. Sorting out the complexities of HIV-1 fitness
  104. Comparing the Ex Vivo Fitness of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates of Subtypes B and C
  105. Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists
  106. Fitness of drug resistant HIV-1: methodology and clinical implications
  107. Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation
  108. In Vitro Intersubtype Recombinants of Human Immunodeficiency Virus Type 1: Comparison to Recent and Circulating In Vivo Recombinant Forms
  109. Human Immunodeficiency Virus Type 1 (HIV-1)Quasispecies at the Sites of Mycobacterium tuberculosis InfectionContribute to Systemic HIV-1 Heterogeneity
  110. Mechanisms Involved in Stimulation of Human Immunodeficiency Virus Type 1 Replication by Aminooxypentane RANTES
  111. Functional Characterization of Chimeric Reverse Transcriptases with Polypeptide Subunits of Highly Divergent HIV-1 Group M and O Strains
  112. A Dual Infection/Competition Assay Shows a Correlation between Ex Vivo Human Immunodeficiency Virus Type 1 Fitness and Disease Progression
  113. Greater Diversity of HIV-1 Quasispecies in HIV-Infected Individuals With Active Tuberculosis
  114. Variable Sensitivity of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates to Inhibition by RANTES Analogs
  115. Quantitation of Human Immunodeficiency Virus Type 1 Group O Load in Plasma by Measuring Reverse Transcriptase Activity
  116. Phylogeny of HIV Type 1 Group O Isolates Based on env Gene Sequences
  117. Molecular Epidemiology of HIV Type 1 Isolates from the Czech Republic: Identification of an env E Subtype Case
  118. Nucleotide Diversity in Three Different Genomic Regions of Venezuelan HIV Type 1 Isolates: A Subtyping Update
  119. Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1
  120. LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression
  121. 3′-Azido-3′-Deoxythymidine (AZT) Mediates Cross-Resistance to Nucleoside Analogs in the Case of AZT-Resistant Human Immunodeficiency Virus Type 1 Variants
  122. Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity
  123. Characterization of the Reverse Transcriptase of a Human Immunodeficiency Virus Type 1 Group O Isolate
  124. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants
  125. Sequence Note : env Gene Characterization of the First HIV Type 1 Group O Spanish Isolate
  126. Point Mutant Frequencies in thepolGene of Human Immunodeficiency Virus Type 1 Are Two- to Threefold Lower Than Those ofenv
  127. Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression.
  128. Sequence Note: env Gene Diversity of HIV Type 1 Isolates from Spain
  129. Molecular Characterization of Human Immunodeficiency Virus Type 1 Isolates from Venezuela
  130. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy
  131. Muscular Changes in Venezuelan Wild Horses Naturally Infected with Trypanosoma evansi
  132. Seroprevalence of retroviruses in the Amazonian rainforest
  133. Methods to Determine HIV-1 Ex Vivo Fitness